Pembrolizumab + lenvatinib for lung diseases

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Nov 2020: Trial registered, NCT04645602
  2. 18 Jul 2025: Trial started, NCT04645602

The trials

NCT04645602: Merck IIT: RRP Pembro and Lenvatinib

State
Under way
Phase
Phase 2
People
20 planned
Started
18 Jul 2025
Primary completion
Dec 2027
Arms
Lenvatinib + Pembrolizumab
Results
None posted
  1. 27 Nov 2020: Trial registered
  2. 18 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.